U.S. Pharmaceuticals & Biotech Leverage Leaders

ACADIA Pharmaceuticals

Market Cap: US$4.2b

A biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States.

Qiagen

Market Cap: US$10.7b

Provides sample to insight solutions that transform biological samples into molecular insights in the Netherlands and internationally.

Exelixis

Market Cap: US$10.1b

An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.

Corcept Therapeutics

Market Cap: US$7.4b

Engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.

Anbio Biotechnology

Market Cap: US$2.3b

Provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally.

Biogen

Market Cap: US$20.4b

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally.

Vaxcyte

Market Cap: US$4.1b

A clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.

ADMA Biologics

Market Cap: US$4.2b

A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.

Stevanato Group

Market Cap: US$6.1b

Engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific.

Regeneron Pharmaceuticals

Market Cap: US$59.3b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

IDEAYA Biosciences

Market Cap: US$2.1b

A precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States.

Kiniksa Pharmaceuticals International

Market Cap: US$2.5b

A biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide.

United Therapeutics

Market Cap: US$14.2b

A biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.

Catalyst Pharmaceuticals

Market Cap: US$2.5b

A commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States.

Neurocrine Biosciences

Market Cap: US$13.2b

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally.

Supernus Pharmaceuticals

Market Cap: US$2.4b

A biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States.

Bio-Techne

Market Cap: US$8.6b

Develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide.

Apogee Therapeutics

Market Cap: US$2.1b

A clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications.

Incyte

Market Cap: US$16.7b

A biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan.

Xenon Pharmaceuticals

Market Cap: US$2.9b

A neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada.

Roivant Sciences

Market Cap: US$8.0b

A clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies.

Ligand Pharmaceuticals

Market Cap: US$3.0b

A biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide.

Denali Therapeutics

Market Cap: US$2.2b

A biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases.

Vertex Pharmaceuticals

Market Cap: US$100.2b

A biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF).

Harmony Biosciences Holdings

Market Cap: US$2.1b

A commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States.

Viking Therapeutics

Market Cap: US$2.7b

A clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.

Krystal Biotech

Market Cap: US$4.2b

A commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.

Metsera

Market Cap: US$3.3b

A clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases.

West Pharmaceutical Services

Market Cap: US$17.8b

Designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.

BioMarin Pharmaceutical

Market Cap: US$11.0b

A biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.

Veracyte

Market Cap: US$2.3b

Operates as a diagnostics company in the United States and internationally.

Immunovant

Market Cap: US$2.6b

A clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases.

Natera

Market Cap: US$22.0b

A diagnostics company, provides molecular testing services worldwide.

Protagonist Therapeutics

Market Cap: US$3.5b

A biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases.

Moderna

Market Cap: US$10.9b

A biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally.

Kymera Therapeutics

Market Cap: US$3.0b

A clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system.